CN117915939A - 肠降血糖素类似物用于血糖控制和体重管理 - Google Patents

肠降血糖素类似物用于血糖控制和体重管理 Download PDF

Info

Publication number
CN117915939A
CN117915939A CN202280057356.1A CN202280057356A CN117915939A CN 117915939 A CN117915939 A CN 117915939A CN 202280057356 A CN202280057356 A CN 202280057356A CN 117915939 A CN117915939 A CN 117915939A
Authority
CN
China
Prior art keywords
weekly dose
dose
week
ggg
weekly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280057356.1A
Other languages
English (en)
Chinese (zh)
Inventor
T·科斯昆
Z·米利切维奇
S·乌尔瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN117915939A publication Critical patent/CN117915939A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Obesity (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN202280057356.1A 2021-06-23 2022-06-22 肠降血糖素类似物用于血糖控制和体重管理 Pending CN117915939A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163213956P 2021-06-23 2021-06-23
US63/213,956 2021-06-23
PCT/US2022/034437 WO2022271767A1 (en) 2021-06-23 2022-06-22 An incretin analog for use in glycemic control and weight management

Publications (1)

Publication Number Publication Date
CN117915939A true CN117915939A (zh) 2024-04-19

Family

ID=82608370

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280057356.1A Pending CN117915939A (zh) 2021-06-23 2022-06-22 肠降血糖素类似物用于血糖控制和体重管理

Country Status (11)

Country Link
US (3) US12496329B2 (enExample)
EP (1) EP4358994A1 (enExample)
JP (1) JP2024524180A (enExample)
KR (1) KR20240024936A (enExample)
CN (1) CN117915939A (enExample)
AU (2) AU2022298662B2 (enExample)
BR (1) BR112023027321A2 (enExample)
CA (1) CA3223313A1 (enExample)
IL (1) IL309604A (enExample)
MX (3) MX2024000213A (enExample)
WO (1) WO2022271767A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102812908B1 (ko) * 2019-08-19 2025-05-28 일라이 릴리 앤드 캄파니 인크레틴 유사체의 제조 방법
CN117320740A (zh) * 2021-02-17 2023-12-29 伊莱利利公司 Gip/glp1双重激动剂治疗方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2548275T3 (es) 2010-03-01 2015-10-15 Eli Lilly And Company Dispositivo de inyección automático con mecanismo de retardo que incluye un elemento de empuje de funcionamiento doble
KR102589234B1 (ko) 2017-11-21 2023-10-16 일라이 릴리 앤드 캄파니 둘라글루티드를 함유하는 조성물 및 사용 방법
AR113486A1 (es) 2017-12-21 2020-05-06 Lilly Co Eli Análogos de incretina y sus usos
TWI767095B (zh) 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3177693A1 (en) 2019-04-05 2020-10-05 Eli Lilly And Company Therapeutic uses of dulaglutide
TW202140058A (zh) 2020-01-30 2021-11-01 美商美國禮來大藥廠 提派肽（ｔｉｒｚｅｐａｔｉｄｅ）之治療用途

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026037397A1 (zh) * 2024-08-16 2026-02-19 江苏恒瑞医药股份有限公司 Glp-1类似物的医药用途

Also Published As

Publication number Publication date
JP2024524180A (ja) 2024-07-05
US20260091088A1 (en) 2026-04-02
US20240325498A1 (en) 2024-10-03
EP4358994A1 (en) 2024-05-01
KR20240024936A (ko) 2024-02-26
AU2022298662A1 (en) 2024-01-18
IL309604A (en) 2024-02-01
AU2025220848A1 (en) 2025-09-11
US20260091087A1 (en) 2026-04-02
MX2024000213A (es) 2024-04-16
MX2025012714A (es) 2025-11-03
AU2022298662B2 (en) 2025-06-05
BR112023027321A2 (pt) 2024-03-12
US12496329B2 (en) 2025-12-16
MX2025012713A (es) 2025-11-03
WO2022271767A1 (en) 2022-12-29
CA3223313A1 (en) 2022-12-29

Similar Documents

Publication Publication Date Title
AU2019309796B2 (en) Methods of using a GIP/GLP1 co-agonist for therapy
CN117915939A (zh) 肠降血糖素类似物用于血糖控制和体重管理
KR102231074B1 (ko) 인슐린 글라진／릭시세나티드 고정비 제형
CN105188736A (zh) 胰岛素给药方案
JP7663559B2 (ja) Ａｃｔｒｉｉ受容体拮抗薬を含む肝疾患または肝臓障害の治療
WO2024006662A1 (en) Tirzepatide compositions and use
TWI837615B (zh) 含腸促胰島素(incretin)類似物之組合物及其用途
Cabré et al. From Current Therapeutics to Multitarget Ligands: A Review of Diabetes Pharmacological Treatments
EA053233B1 (ru) Способы применения и композиции, включающие аналог инкретина
BR122025000167A2 (pt) Uso de um polipeptídeo, composição que compreende trirreceptor ggg, e dispositivo
US20240366728A1 (en) Treatment of Diabetes Mellitus
RU2838150C1 (ru) Лечение заболевания или нарушения со стороны печени, предусматривающее применение антагонистов рецепторов actrii
WO2023235724A1 (en) Methods of using a gcg/glp1 co-agonist for therapy
KR20250046317A (ko) 요법에 사용하기 위한 gip/glp1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination